We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Serum Brain-Derived Neurotrophic Factor as a Predictor of Incident Dementia

Kenji Hashimoto, PhD1
[+] Author Affiliations
1Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
JAMA Neurol. 2014;71(5):653. doi:10.1001/jamaneurol.2013.6414.
Text Size: A A A
Published online


To the Editor I read with great interest the article by Weinstein et al1 describing the association between serum brain-derived neurotrophic factor (BDNF) levels and the risk for dementia. In this community-based cohort study of 2131 participants, with a 10-year follow-up, 140 participants developed dementia, 117 of whom had Alzheimer disease (AD). They found that dementia-free participants with higher serum BDNF levels were less likely to develop dementia and AD, after controlling for age, sex, and cohort. Interestingly, this significant association between serum BDNF and the risk for incident dementia and AD was confined to women. In contrast, BDNF gene variants were not associated with AD risk. Their study suggests that low serum BDNF may play a role in the development of AD, especially in older women, the group at highest risk for AD, and that serum BDNF may also serve as a novel predictor of dementia and AD in healthy adults.1


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





May 1, 2014
Galit Weinstein, PhD; Sudha Seshadri, MD
1Department of Neurology, Boston University School of Medicine, Boston, Massachusetts2The Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts
JAMA Neurol. 2014;71(5):653-654. doi:10.1001/jamaneurol.2014.215.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...